The effects of altitude training on hormonal response in professional cyclists by Raphael Faiss, Bastien Krumm, Basile Moreillon, Lena Mettraux, Julian Wackernell, James Spragg, Martin Faulhaber

“…Additional blood samples were taken two weeks before, 72 h after and 10 days after the training camp to monitor i) steroidal hormones (testosterone), and ii) endocrine response (Insuline-like growth factor-1 (IGF-1)). Results At the end of the altitude training camp, Hbmass had increased in average by 3.7% (+40 g, p<0.001) while PV was decreased by 5.7% (-216 mL, p=0.002). …”
Get full text

Skipping Breakfast Is Associated with an Atherogenic Lipid Profile in Overweight and Obese Prepubertal Children by A. Blasetti, S. Franchini, V. Castorani, L. Comegna, E. Fornari, F. Daniele, G. Prezioso, C. Piona, V. Federico, D. Zona, I. Bresadola, F. Chiarelli, C. Maffeis

“…Hormones, in particular, insulin-like growth factor-1 (IGF-1), may potentially play a role in the metabolic profile of breakfast skippers. …”
Get full text

Reproductive performance of female largemouth bass (Micropterus salmoides) broodstock was enhanced by dietary small peptides by Jie Wei, Mingwei Tao, Jiaming Huang, Hangxian Zhou, Qiyou Xu

“…The mRNA expression levels of vgr (1.90 ± 0.29), insulin-like growth factor-1 (1.53 ± 0.67), steroidogenic acute regulatory protein (2.59 ± 0.78), fshr (1.97 ± 0.35) and cyp17a (2.78 ± 1.32) in gonad were up-regulated in the HS group (P < 0.05). …”
Get full text

Deciphering key nano-bio interface descriptors to predict nanoparticle-induced lung fibrosis by Jiayu Cao, Yuhui Yang, Xi Liu, Yang Huang, Qianqian Xie, Aliaksei Kadushkin, Mikhail Nedelko, Di Wu, Noel J. Aquilina, Xuehua Li, Xiaoming Cai, Ruibin Li

“…The fibrogenic potential of MeONPs in mouse lungs was assessed by examining collagen deposition and growth factor release. Random forest classification was employed for analyzing in chemico, in vitro and in vivo data to identify predictive descriptors. …”
Get full text

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with lim... by John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor

“…Using an anti-epidermal growth factor receptor (EGFR) arm as a proof-of-concept, tumor-associated antigen paired with a single-chain HLA-A *02:01/CMVpp65 pMHC fusion moiety, we demonstrate in vitro that the IL-2-armored GPS modality robustly expands CMVpp65-specific CD8+ effector memory T cells and induces potent cytotoxic activity against target cancer cells. …”
Get full text

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

“…Abstract Background Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) remains a significant hurdle for patients with EGFR‐mutated non‐small cell lung cancer (NSCLC), particularly those lacking the EGFRT790M. …”
Get full text

Cerebral microvascular density, blood-brain barrier permeability, and support for neuroinflammation indicate early aging in a Marfan syndrome mouse model by Tala Curry-Koski, Tala Curry-Koski, Liam P. Curtin, Mitra Esfandiarei, Mitra Esfandiarei, Mitra Esfandiarei, Theresa Currier Thomas, Theresa Currier Thomas, Theresa Currier Thomas, Theresa Currier Thomas

“…IntroductionMarfan Syndrome (MFS) is a connective tissue disorder due to mutations in fibrillin-1 (Fbn1), where a Fbn1 missense mutation (Fbn1C1039G/+) can result in systemic increases in the bioavailability and signaling of transforming growth factor-β (TGF-β). In a well-established mouse model of MFS (Fbn1C1041G/+), pre-mature aging of the aortic wall and the progression of aortic root aneurysm are observed by 6-month-of-age. …”
Get full text

Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk by Xinyu Ren, Tong Zhou, Yu Song, Huanwen Wu, Jeff Chou, Lance D. Miller, Zhiyong Liang, Songjie Shen

“…Intrinsic subtypes (basal-like, immune-enhanced, human epidermal growth factor receptor-2 [HER2]-enriched and luminal A/B) and tumor environmental immunity were evaluated using expression profiles of a 72-gene panel. …”
Get full text

Cooling and Sterile Inflammation in an Oxygen-Glucose-Deprivation/Reperfusion Injury Model in BV-2 Microglia by Jana Lücht, Nele Rolfs, Sylvia J. Wowro, Felix Berger, Katharina R. L. Schmitt, Giang Tong

“…Furthermore, inducible nitric oxide synthase (iNOS), ionized calcium-binding adaptor molecule 1 (Iba1), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-1α (IL-1α), monocyte chemotactic protein 1 (MCP-1), transforming growth factor β (TGFβ), CIRBP, and RBM3 gene expressions were assessed via reverse transcription polymerase chain reaction, and TNF-α, IL-6, and IL-1β releases into the cultured supernatants were assessed via enzyme-linked immunosorbent assays (ELISA). …”
Get full text

Network and systems biology approaches help investigate gene regulatory interactions between Salmonella disease and host in chickens: Model‐based in silico evidence combined with g... by Reza Tohidi, Hoda Javaheri Bargourooshi, Arash Javanmard

“…These include inducible nitric oxide synthase, NRAMP1, immunoglobulin light chain (IgL), transforming growth factor B family (TGFb2, TGFb3 and TGFb4), interleukin 2 (IL2), apoptosis inhibitor protein 1 (IAP1), TLR4, myeloid differentiation protein 2 (MD2), IFNγ, caspase 1 (CASP1), lipopolysaccharide‐induced tumour necrosis factor (LITAF), cluster of differentiation 28 (CD28) and prosaposin (PSAP). …”
Get full text

Machine learning for predicting neoadjuvant chemotherapy effectiveness using ultrasound radiomics features and routine clinical data of patients with breast cancer by Pu Zhou, Pu Zhou, Hongyan Qian, Pengfei Zhu, Jiangyuan Ben, Jiangyuan Ben, Guifang Chen, Qiuyi Chen, Lingli Chen, Jia Chen, Ying He, Ying He

“…SHAP analysis indicated that participants with a high Rad score, PR-negative, ER-negative and human epidermal growth factor receptor-2 (HER-2) positive were more possibly to reach pCR. …”
Get full text

ATP1B3 may promote glioma proliferation and migration through MAPK/NF-KB signaling pathway by Qikang Yan, Quan Sun, Yan Feng, Qingyun Hu, Jinling Zhu

“…Cyclin D1 and vascular endothelial growth factor A(VEGFA) expression alterations following ATP1B3 deletion were identified using the WB assay. …”
Get full text

Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack by Bingxun Wang, Yongqing Liu, Wenya Han, Bing Li, Pang Jie, Wenwen Yang, Zengcai Ma, Zesheng Xu

“…Before and after treatment, cardiac function indicators (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular posterior wall thickness (LVPWT)), vascular endothelial function indicators (sICAM-1, endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF)), inflammatory factors (NALP3, MMP-9, MMP-13) levels, changes in immune cell populations (CD3+ lymphocytes, CD3+CD4+ lymphocytes, CD3+CD8+ lymphocytes ratio, and CD3+CD4+/CD3+CD8+ ratio) were compared, and the incidence of adverse reactions was recorded. …”
Get full text

Etelcalcetide: What we know eight years since its approval by Pedro Freitas, Luciano Pereira

“…Results: Regarding bone and mineral metabolism, etelcalcetide is effective in reducing serum levels of parathormone (PTH), calcium, phosphate and fibroblast growth factor 23 (FGF23). Preliminary data have highlighted its role in reducing bone turnover and improving mineralization and preservation of bone structure, indicating a possible positive impact on renal osteodystrophy. …”
Get full text

FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis by Amaya Lopez-Pascual, Eva Santamaria, Nuria Ardaiz, Iker Uriarte, Tiffany Palmer, Anne-Renee Graham, Celia Gomar, Roberto C. Barbero, M. Ujue Latasa, Maria Arechederra, Jesus M. Urman, Carmen Berasain, Antonio Fontanellas, Carlos L. del Rio, Maite G. Fernandez-Barrena, Paolo G.V. Martini, Joshua R. Schultz, Pedro Berraondo, Matias A. Avila

“…This study explores mRNA-based therapies delivering fibroblast growth factor 21 (FGF21) and apolipoprotein A1 (APOA1), alone and in combination, for treating experimental AP. …”
Get full text

HIF-1α and VEGF Immunophenotypes as Potential Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature by Dimitra P. Vageli, Panagiotis G. Doukas, Dimitrios Georgiou, Michailangelos P. Prokopiou, Nefeli E. Ladaki, Androniki Papadopoulou, Sotirios G. Doukas, Konstantina Zacharouli, Konstantinos P. Makaritsis, Maria Ioannou

“…Background: Hypoxia-inducible factor 1 alpha (HIF-1α) and its related vascular endothelial growth factor (VEGF) may play a significant role in atherosclerosis and their targeting is a strategic approach that may affect multiple pathways influencing disease progression. …”
Get full text

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis by Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Pierluigi De Santis, Roberta Caputo, Carmine De Angelis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Martina Pagliuca, Michelino De Laurentiis

“…Background: The combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC). …”
Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…To further assess the reproducibility of clinical trial results, we reconstructed the “KN024 look-alike” cohort by excluding patients with an Eastern Cooperative Oncology Group-performance status (ECOG-PS)≥2, those requiring corticosteroids with doses ≥10 mg of prednisolone/equivalent, patients with positive/unknown epidermal growth factor receptor/anaplastic lymphoma kinase genotype, and those with pre-existing autoimmune disease. …”
Get full text